**Core tip:** In total, 11 case reports and 18 case series were systematically reviewed. These articles stated the main causes of sinusoidal obstruction syndrome (SOS) and summarized the common clinical symptoms and abnormal laboratory indicators. Numerous characteristic magnetic resonance imaging features could provide more valuable information for early diagnosis of SOS.

INTRODUCTION
============

Sinusoidal obstruction syndrome (SOS) is a rare liver vascular injury disease, characterized by damage to small hepatic vessels, affecting particularly the sinusoidal endothelium, which result in complications such as intrahepatic congestion, liver damage, and portal hypertension\[[@B1]\]. SOS was previously called as hepatic veno-occlusive disease until some researchers suggested that the main site of toxic injury is hepatic sinusoidal endothelium rather than hepatic veins\[[@B2]\]. Hepatomegaly, ascites, and elevated serum bilirubin levels are the characteristic manifestations of SOS. In addition, severe SOS is associated with a high mortality rate and most deaths result from multi-organ failure\[[@B3]\].

Although liver biopsy is the gold standard for the diagnosis of SOS, leukopenia and poor liver function resulting from hematological diseases or advanced tumors make this operation difficult. The Baltimore criteria, the modified Seattle criteria, and the European Society for Blood and Marrow Transplantation criteria are the three main criteria for diagnosing SOS\[[@B4],[@B5]\]. However, these criteria are usually appropriated for SOS secondary to haemopoietic stem cell transplantation (HSCT), including a little of clinical information but not involving imaging findings. In recent years, magnetic resonance imaging (MRI) has been increasingly used to detect and evaluate liver diseases. In 2017, Chinese scholars combined the etiologies of SOS in Chinese and proposed the new diagnostic criteria for SOS, namely, the Nanjing criteria. The criteria focus on the diagnosis of SOS caused by pyrrolidine alkaloids (PAs), and incorporate clinical information and imaging findings\[[@B6]\].

Considering the complexity of etiologies and the limitation of liver biopsy, non-invasive imaging methods are significant for SOS differential diagnosis. This systematic review collected the current research on SOS, aiming at generalizing the common etiologies and clinical symptoms of SOS and summarizing the characteristic MRI imaging features for providing more valuable information in SOS early diagnosis.

MATERIALS AND METHODS
=====================

Protocol and registration
-------------------------

This systematic review was registered at the international prospective register of systematic reviews platform (PROSPERO; registration number: CRD42019127258). This study followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Search strategy
---------------

We searched all the literature from PubMed, Web of science, Cochrane Library, Wanfang Data, China Knowledge Resource Integrated, and VIP databases. The following set of keywords was used for the English search strategy: \[(sinusoidal obstruction syndrome) OR (hepatic veno-occlusive disease)\] AND \[(MRI) OR (magnetic resonance imaging) OR (MR imaging)\]. Chinese search items were used in the latter three databases, as follows: \[(Gandou Zuse) OR (Gan Xiaojingmai Bise)\] AND \[(Cigongzhen) OR (MRI)\]. Last search was performed on January 28, 2019.

Study selection
---------------

All articles related to SOS etiologies, clinical symptoms, and MRI findings were considered. The exclusion criteria were as follows: (1) Duplicate publications among databases; (2) Duplicate publications by the same author; (3) Letter, comments, or conference papers; (4) Reviews; (5) Neither in English nor in Chinese; (6) Not related to human; (7) Not related to this systematic review; and (8) Cannot extract detailed data.

Data extraction
---------------

Twenty-nine studies were included in the final analysis, and none of them were randomized controlled trials or cohort studies. We classified the included studies into two categories: Case reports and case series. If detailed data could be extracted for every patient in studies, it would be classified as case reports, otherwise case series.

The following data were collected by two independent investigators: Author, country, published year, patient enrollment, number, age, sex, primary disease, etiology, time of duration, diagnosis method, MRI equipment information, scanning sequence, frequent clinical symptoms, laboratory indexes, and main MRI findings. A third author participated in a disagreement in the findings of two authors, which was solved by discussion.

Study quality
-------------

Given the characteristics of our included articles, there was no ready-made quality assessment scale for case reports and case series. Therefore, we referred to some literature\[[@B7]\] and revised the existing quality assessment scale as follows: (1) Patient enrollment: Are the patients consecutively and prospectively enrolled? (2) Demographic data: Is the basic information of sex and age clearly reported? (3) Clinical presentation data: Are the clinical symptoms clearly reported? (4) Laboratory test data: Are the laboratory test data clearly reported? (5) Diagnostic workup: Is the diagnosis based on pathological results? and (6) Imaging findings: Are the imaging manifestations clearly reported?

Notably, case reports were not related to patient enrollment, therefore patient enrollment was not assessed in the study quality.

RESULTS
=======

Search results
--------------

A total of 251 articles were initially searched. After removal of duplicates (*n* = 37), 214 articles were subjected to screening of abstracts and full-texts. Following careful review of abstracts and full-texts, a total of 185 articles were excluded due to not meeting the inclusion criteria. Finally, 29 articles met the inclusion criteria and were included in this systematic review (Figure [1](#F1){ref-type="fig"}).

![Flowchart of study inclusion.](WJCC-7-2746-g001){#F1}

Characteristics of the studies
------------------------------

Among 29 articles included in this systematic review, 20 were in Chinese and 9 in English. According to the case number and information integrity of the literature, 29 articles were classified as either case reports (*n* = 11) or case series (*n* = 18).

According to the quality assessment criteria above, we conducted the quality evaluation of all the included literature. The evaluation results are shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, and we used two stars to represent the highest quality. The characteristic information of all the patients in 29 studies is shown in Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}.

###### 

Quality assessment of 11 case reports

  **Case No**.   **Authors**                     **Demographic data**   **Clinical symptom data**   **laboratory examination data**   **Diagnostic workup**   **Imaging findings**
  -------------- ------------------------------- ---------------------- --------------------------- --------------------------------- ----------------------- ----------------------
  1              Hu et al\[[@B17]\]              \*\*                   \*\*                        \*\*                              \*                      \*\*
  2              Kang et al\[[@B18]\]            \*\*                   \*\*                        \*\*                              \*\*                    \*\*
  3              Yan\[[@B20]\]                   \*\*                   \*\*                        \*\*                              \*                      \*\*
  4              Yoneda et al\[[@B21]\]          \*\*                   \*                          \*                                \*\*                    \*
  5              Kawa et al\[[@B31]\]            \*\*                   \*                          \*\*                              \*\*                    \*\*
  6              Mortelé et al\[[@B8]\]          \*\*                   \*\*                        \*                                \*\*                    \*\*
  7              van den Bosch et al\[[@B13]\]   \*\*                   \*\*                        \*\*                              \*\*                    \*\*
  8              Marasco et al\[[@B9]\]          \*\*                   \*                          \*                                \*                      \*\*
  9              Liu et al\[[@B32]\]             \*\*                   \*                          \*\*                              \*\*                    \*
  10             Choi et al\[[@B28]\]            \*\*                   \*                          \*\*                              \*\*                    \*\*
  11             Arakawa et al\[[@B29]\]         \*\*                   \*                          \*\*                              \*\*                    \*\*

\*: Quality assessment score.

###### 

Quality assessment of 18 case series

  **Case No**.   **Authors**              **Patients enrollment**   **Demographic data**   **Clinical symptom data**   **Laboratory examination data**   **Diagnostic workup**   **Imaging findings**
  -------------- ------------------------ ------------------------- ---------------------- --------------------------- --------------------------------- ----------------------- ----------------------
  1              Chen et al\[[@B33]\]     \*                        \*\*                   \*                          \*                                \*\*                    \*\*
  2              Xu\[[@B34]\]             \*                        \*\*                   \*                          \*                                \*\*                    \*\*
  3              Ye et al\[[@B35]\]       \*                        \*\*                   \*                          \*\*                              \*\*                    \*\*
  4              Zheng et al\[[@B36]\]    \*                        \*\*                   \*                          \*                                \*                      \*\*
  5              Ren et al\[[@B37]\]      \*                        \*\*                   \*\*                        \*\*                              \*\*                    \*\*
  6              Geng e*t al*\[[@B38]\]   \*                        \*\*                   \*                          \*                                \*                      \*\*
  7              Chen et al\[[@B39]\]     \*                        \*\*                   \*                          \*                                \*\*                    \*\*
  8              Zhang et al\[[@B40]\]    \*                        \*\*                   \*                          \*                                \*\*                    \*\*
  9              Li et al\[[@B41]\]       \*                        \*\*                   \*                          \*\*                              \*\*                    \*\*
  10             Hu et al\[[@B42]\]       \*                        \*\*                   \*                          \*                                \*                      \*\*
  11             Li et al\[[@B43]\]       \*                        \*\*                   \*                          \*                                \*                      \*\*
  12             Li et al\[[@B44]\]       \*                        \*\*                   \*                          \*\*                              \*                      \*\*
  13             Yu et al\[[@B24]\]       \*                        \*\*                   \*                          \*                                \*                      \*\*
  14             Rong\[[@B45]\]           \*                        \*\*                   \*\*                        \*                                \*                      \*\*
  15             Pei et al\[[@B46]\]      \*                        \*\*                   \*                          \*                                \*\*                    \*\*
  16             Zhou et al\[[@B47]\]     \*                        \*\*                   \*                          \*                                \*\*                    \*\*
  17             Guo\[[@B48]\]            \*                        \*\*                   \*                          \*                                \*                      \*\*
  18             Yang\[[@B49]\]           \*                        \*\*                   \*\*                        \*\*                              \*                      \*\*

\*: Quality assessment score.

###### 

Characteristic information of patients in 11 case reports

  **No**.   **Authors**                     **Country**   **Publication year**   **Patient No**.   **Sex (male/fe-male)**   **Age (average)**   **Primary disease**                                                                                   **Etiology**                                                  **Time of duration**                                   **Diagnostic method**
  --------- ------------------------------- ------------- ---------------------- ----------------- ------------------------ ------------------- ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------ -------------------------------------------------------------
  1         Hu et al\[[@B17]\]              China         2014                   2                 (2/0)                    71/63               /                                                                                                     Tusanqi                                                       UK                                                     Clinical manifesta-tions + laboratory examination + imaging
  2         Kang et al\[[@B18]\]            China         2015                   1                 Female                   62                  /                                                                                                     Tusanqi                                                       UK                                                     Biopsy
  3         Yan\[[@B20]\]                   China         2015                   1                 Male                     65                  Liver cirrhosis                                                                                       Tusanqi (300g)                                                UK                                                     Clinical manifesta-tions + laboratory examination + imaging
  4         Yoneda et al\[[@B21]\]          Japan         2015                   1                 Female                   75                  Hepatic metastasis of colonic carcinoma                                                               Preoperative chemotherapy (Pmab + m-FOLFOX6)                  6 cycles (preoperative) + 4.5 month (postopera-tive)   Biopsy
  5         Kawa et al\[[@B31]\]            Japan         2016                   1                 Female                   40                  Rectal cancer underwent high anterior resection and partial liver resection due to liver metastasis   Oxaliplatin-based chemo-therapy (mFOLFOX6)                    6 mo                                                   Biopsy
  6         Mortelé et al\[[@B8]\]          USA           2001                   1                 Male                     32                  /                                                                                                     "Poppers", a recreational drug used during anal intercourse   UK                                                     Biopsy
  7         van den Bosch et al\[[@B13]\]   Netherlands   1999                   2                 (1/1)                    17/34               Lymph-ocytic leukemia/acute myeloid leukemia                                                          Bone marrow transplanta-tion                                  UK                                                     Percuta-neous puncture + histological examination/autopsy
  8         Marasco et al\[[@B9]\]          UK            2016                   1                 Male                     50                  Ulcerative colitis                                                                                    6-thioguanine                                                 UK                                                     Clinical manifesta-tions + imaging
  9         Liu et al\[[@B32]\]             China         2017                   1                 Male                     52                  Gastric adenocarcinoma                                                                                S-1 and oxaliplatine (SOX) regimen                            Five cycles                                            Biopsy
  10        Choi et al\[[@B28]\]            Korea         2016                   1                 Female                   22                  Laparo-scopic right hemicolectomy for ascending colon cancer                                          Oxaliplatin-based adjuvant chemo-therapy                      Four cycles                                            Biopsy
  11        Arakawa et al\[[@B29]\]         Japan         2013                   1                 Female                   40                  Low anterior resection for advanced rectal cancer                                                     Oxaliplatin-based chemo-therapy                               Eight cycles                                           Biopsy

UK: Unknown.

###### 

Characteristic information of patients in 18 case series

  **No**.   **Authors**             **Country**        **Publication year**   **Patient enroll-ment**   **Patient No**.   **Year range**   **Sex (male/fe-male)**   **Age (range, average)**   **Primary disease**                                          **Etiology**                                                   **Time of duration**   **Dia-gnostic method**
  --------- ----------------------- ------------------ ---------------------- ------------------------- ----------------- ---------------- ------------------------ -------------------------- ------------------------------------------------------------ -------------------------------------------------------------- ---------------------- ------------------------------------------------------------------------------
  1         Chen et al\[[@B33]\]    China              2016                   Retro-spective            8                 2006-2013        5/3                      21-67, 42                  /                                                            Tusanqi                                                        3-18 mo                Biopsy (5) Clinical manifesta-tions + imaging (3)
  2         Xu\[[@B34]\]            China              2015                   Retro-spective            11                2004-2012        9/2                      37-65, 49                  /                                                            Tusanqi (350-800 g)                                            15-50 d                Biopsy (2) Clinical manifesta-tions + imaging (9)
  3         Ye et al\[[@B35]\]      China              2015                   Retro-spective            20                2010-2012        1/19                     36-76, 51                  Trauma or stroke                                             Tusanqi                                                        10 d-6 mo              Biopsy (12) Clinical manifesta-tions + laboratory examina-tion + imaging (8)
  4         Zheng et al\[[@B36]\]   China              2015                   Retro-spective            4                 2012-2014        4/0                      45-66                      Alcoholic liver cirrhosis, trauma, body pain                 Tusanqi (600-1500 g)                                           1-4 mo                 Clinical manifesta-tions + imaging
  5         Ren et al\[[@B37]\]     China              2017                   Retro-spective            239               2010-2017        151/88                   15-86 (59.6 ± 10.9)        Trauma, hypertension, extravasated blood, URI                Tusanqi                                                        UK                     Biopsy (48), Clinical manifesta-tions + imaging
  6         Geng et al\[[@B38]\]    China              2009                   Retro-spective            4                 2007-2008        1/3                      42-72, 57                  /                                                            Tusanqi                                                        12-60 d                Clinical manifesta-tions
  7         Chen et al\[[@B39]\]    China              2012                   Retro-spective            45                1998-2011        23/22                    33-73, 57                  Trauma                                                       Tusanqi                                                        2-16 wk                Biopsy (21) Clinical manifesta-tions + laboratory examina-tion + imaging (8)
  8         Zhang et al\[[@B40]\]   China              2012                   Retro-spective            15                2005-2011        12/3                     42-65                      /                                                            Tusanqi                                                        1-6 mo                 Biopsy (6) DSA (1) Clinical manifesta-tions + laboratory examina-tion + MRI
  9         Li *et a*l\[[@B41]\]    China              2011                   Retro-spective            4                 2009-2011        2/2                      27-63, 35                  /                                                            Tusanqi (3), chemo-therapy (1)                                 Tusanqi (1-3 mo)       Biopsy (2) Clinical manifesta-tions + imaging
  10        Hu et al\[[@B42]\]      China              2011                   Retro-spective            5                 2006-2011        4/1                      40-60                      Trauma history (3), health fitness (1)                       Tusanqi                                                        ≥1 mo                  Biopsy (2) Clinical manifesta-tions + imaging
  11        Li et al\[[@B43]\]      China              2015                   Retro-spective            4                 2009-2014        3/1                      35-61                      Myocar-dial infarction (1)                                   Tusanqi                                                        /                      UK
  12        Li et al\[[@B44]\]      China              2014                   Retro-spective            8                 2011-2014        5/3                      21-71, 44.9                /                                                            Tusanqi (2) Chemo-therapy or immune suppres-sive therapy (9)   /                      Biopsy
  13        Yu et al\[[@B24]\]      China              2013                   Retro-spective            6                 2002-2012        1/5                      10-62 (36.5 ± 20.2)        Trauma (5) Irregular menstrua-tion (1)                       Tusanqi (200-700 g)                                            8-30 d                 Biopsy
  14        Rong\[[@B45]\]          China              2015                   Retro-spective            51                2009-2015        36/15                    20-79                      Drinking (14) Hyperten-sion (1) Diabetes (1) TB (1) RA (1)   Tusanqi (27) HSCT (4),                                         3 d-4 yr               Biopsy (6) Clinical manifesta-tions + imaging
  15        Pei et al\[[@B46]\]     China              2010                   Retro-spective            6                 2006-2008        2/4                      17-46                      /                                                            Tusanqi (5)                                                    30 d                   Biopsy (3) Clinical manifesta-tions + imaging
  16        Zhou et al\[[@B47]\]    Hong Kong, China   2014                   Retro-spective            16                2009-2011        12/4                     22-72, 55.6                /                                                            Intake of *Gynura segetum*                                     UK                     Liver transplanta-tion (1) Clinical manifesta-tions
  17        Guo\[[@B48]\]           China              2015                   Retro-spective            12                2013-2014        9/3                      45-62, 53                  /                                                            Tusanqi                                                        UK                     Clinical manifesta-tions + imaging
  18        Yang\[[@B49]\]          China              2018                   Retro-spective            39                2010-2016        9/30                     36-74, 59.18 ± 9.36        /                                                            Pyrrolizi-dine alkaloid (PA)--containing herbals               UK                     Clinical manifesta-tions + imaging

UK: Unknown.

Etiologies and clinical symptoms of SOS
---------------------------------------

Eleven cases reports included 13 individual cases of SOS from 6 counties (USA, Netherlands, UK, Japan, Korea, and China). These patients were admitted from 1999 to 2017. Among the 13 cases, 7 were males and 6 were females (average age: 47.9 ± 18.0; age range: 17-75).

The clinical characteristics of 13 cases are shown in Table [5](#T5){ref-type="table"}. Five cases were secondary to chemotherapy after liver metastases. The chemotherapy cycles ranged from 4 to 8. All the 5 cases presented no obvious clinical symptoms, but the laboratory examination data indicated different degrees of liver damage. In addition, 4 cases were caused by Tusanqi. Ascites was the most common clinical symptom.

###### 

Clinical characteristics of 13 patients in 11 case reports, *n* (%)

  **Variable**                                                   **No. of patients with available data**   **Value**
  -------------------------------------------------------------- ----------------------------------------- -----------
  Sex (male/female)                                              13                                        7/6
  Age, yr                                                        13                                        47.9
  **Underlying disease**                                                                                   
  None                                                           13                                        4 (30.8)
  Postoperative liver metastasis of advanced colorectal cancer   13                                        3 (23.1)
  Leukemia                                                       13                                        2 (15.4)
  Liver cirrhosis                                                13                                        1 (7.7)
  Hepatic metastasis of colonic carcinoma                        13                                        1 (7.7)
  Gastric adenocarcinoma                                         13                                        1 (7.7)
  **Clinical symptom**                                                                                     
  Ascites                                                        13                                        7 (53.8)
  Abdominal swelling                                             13                                        4 (30.8)
  Pleural effusion                                               13                                        4 (30.8)
  Hepatomegaly                                                   13                                        3 (23.1)
  Jaundice                                                       13                                        3 (23.1)
  Stomach ache                                                   13                                        3 (23.1)
  Weak                                                           13                                        3 (23.1)
  Lower limbs edema                                              13                                        2 (15.4)
  Lower limbs lassitude                                          13                                        2 (15.4)
  Loss of appetite                                               13                                        2 (15.4)
  Yellow urine                                                   13                                        2 (15.4)
  Oliguria                                                       13                                        1 (7.7)
  Esophageal varices                                             13                                        1 (7.7)
  PVH                                                            13                                        1 (7.7)
  **Etiology**                                                                                             
  Chemotherapy                                                   13                                        5 (38.5)
  Tusanqi                                                        13                                        4 (30.8)
  Hematopoietic stem cell transplantation                        13                                        2 (15.4)
  "Poppers," a recreational drug used during anal intercourse    13                                        1 (7.7)
  Drug toxicity (6-thioguanine)                                  13                                        1 (7.7)
  **Laboratory index**                                                                                     
  ALP, U/L                                                       11                                        206.4
  ALT, U/L                                                       9                                         836.2
  AST, U/L                                                       8                                         1284.25
  GGT, U/L                                                       7                                         155.42
  LDH, U/L                                                       3                                         5608.33
  TBil, μmol/L                                                   9                                         63.11
  DBil, μmol/L                                                   5                                         35
  Alb, g/L                                                       5                                         37.52
  TBA, g/L                                                       2                                         27.65
  T-CHE, U/L                                                     2                                         3242
  TP, g/L                                                        1                                         47.7
  CA-125, U/mL                                                   1                                         299.1

PVH: Portal hypertension; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transpeptidase; TBil: Total bilirubin; DBil: Direct bilirubin; prothrombin time; ALB: Albumin; TBA: Total bile acid.

Seventeen out of 18 case series were reported by Chinese researchers, and the other one was reported by researchers in Hong Kong, China. All the patients were admitted from 1998 to 2017. Patient enrollment was neither consecutive nor prospective in any case series. Eighteen case series included 497 patients, including 310 males and 187 females. All studies had specific demographic data.

Of the 18 cases series, the patients in 8 cases series were reported to have underlying diseases, including trauma, stroke, alcoholic liver cirrhosis, chronic body pain, hypertension, myocardial infarction, drinking, diabetes, diseases of the respiratory system (tuberculosis and upper respiratory infection), and some diseases related to Chinese medicine (menstrual disorder). SOS in about 465 (93.6%) patients was caused by PAs (Tusanqi), and the time of duration from 10 days to 18 months. Five cases were secondary to tumor chemotherapy or immunotherapy, and four were caused by HSCT. The rest of the patients had no obvious inducing factors.

Not all the 497 patients had detailed records of clinical manifestations and laboratory examination data. Most of the studies recorded the presence or absence of clinical symptoms and described the variation trend of laboratory indicators. Stomach ache, abdominal swelling, and jaundice were the major three symptoms. More serious symptoms were reported in 3 cases series, including hepatic encephalopathy, upper gastrointestinal bleeding, and yellow urine staining. The increase of laboratory indexes, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), total bilirubin (TBil), and direct bilirubin (DBil), were reported in 16 case series.

Characteristic MRI imaging features
-----------------------------------

Of all the 510 patients, 250 underwent 256 MRI examinations (12 patients underwent 18 MRI examinations in one study). The scanning sequences included T1WI, T2WI, and multi-phase dynamic enhanced scanning. Among 256 MRI examinations, 8 cases underwent diffusion weighted imaging scans, 22 cases underwent hepatobiliary scans, and 39 cases underwent susceptibility weighted imaging (SWI) scans. In all valid imaging data, the main MRI imaging features were heterogeneous signals on T1WI/T2WI, heterogeneous enhancement, and ascites. All characteristic MRI imaging features are shown in Table [6](#T6){ref-type="table"}.

###### 

Magnetic resonance imaging features of all 256 examinations, *n* (%)

  **MRI feature**                                               **Number of cases**
  ------------------------------------------------------------- ---------------------
  Heterogeneous signals on T1WI/T2WI                            221 (86.3)
  Heterogeneous enhancement                                     189 (73.8)
  Ascites                                                       189 (73.8)
  Hepatomegaly                                                  167 (65.2)
  Narrowing and blurring of intrahepatic IVC                    167 (56.6)
  Gallbladder wall edema                                        121 (47.3)
  Narrowing of three main hepatic veins                         105 (41.1)
  Edema around the portal vein, \"cuffing\"                     90 (35.2)
  Narrowing and blurring of intrahepatic veins                  52 (20.3)
  Collateral circulation opens                                  37 (14.6)
  Splenomegaly                                                  32 (12.5)
  Narrowing and blurring of portal vein                         28 (10.9)
  Dilated and twisted small vessels                             17 (6.6)
  Hypo-intensity on HBP                                         17 (6.6)
  Dilated hepatic arteries                                      12 (4.7)
  \"Halo signs\" around the hepatic vein and intrahepatic IVC   11 (4.3)
  Restricted diffusion                                          5 (2.0)
  Gastrointestinal edema                                        4 (1.6)
  Multiple hyperplasia nodules                                  2 (0.8)
  Caudate lobe enlargement                                      2 (0.8)
  Focal nodules or masses                                       1 (0.4)
  Dilated spleen vein                                           1 (0.4)

MRI: Magnetic resonance imaging; IVC: Inferior vena cava.

DISCUSSION
==========

This article systematically reviewed the current available literature related to the etiologies, clinical symptoms, and MRI imaging findings of SOS. In the West, SOS was mostly secondary to HSCT, while some SOS developed in the process of chemotherapy for hepatic metastatic tumor. However, the toxic effects of some special drugs also resulted in the occurrence of SOS, although they have been rarely reported\[[@B8],[@B9]\]. In the East, especially in China, SOS was often caused by Tusanqi, a plant containing PA that always be used in the herbal medicines. Ascites, abdominal pain and swelling, and jaundice were the common symptoms. ALT, AST, ALP, GGT, and TBil were the main laboratory indicators for diagnosing liver damage. Heterogeneous signals on T1WI/T2WI, heterogeneous enhancement of liver parenchyma, ascites, hepatomegaly, narrowing and blurring of inferior vena cava (IVC) and three main hepatic veins, edema around the portal vein, and gallbladder wall edema were the most common MRI imaging features of SOS.

Our article presents several advantages. First of all, this is the first systematic review that combined clinical information and MRI imaging features of SOS. Second, English and Chinese databases were retrieved at the same time for ensuring the comprehensiveness of this review. To avoid duplicate articles or data, the rigorous studies screening program was also developed. In addition, we formulated the unique quality evaluation criteria based on the nature of the included literature.

SOS was first reported as an early complication of HSCT in 1979\[[@B10]\]. The cause of the disease is usually associated with sinusoidal endothelial cell cytotoxicity induced by a series of conditioning treatments prior to HSCT. The overall incidence of SOS is related to the diagnosis criteria and type of transplantation, with an incidence of up to 60%\[[@B11]\]. Some risk factors for SOS related to HSCT have been identified, including existing liver disease (chronic hepatitis, liver fibrosis, and cirrhosis), prior history of liver radiant examination, and the effects of some drugs used in the process of conditioning\[[@B12]\]. In addition, Al Jefri et al\[[@B4]\] pointed out that if a patient was too young or too old, or accepted allogeneic transplantation, the possibility of morbidity was greatly increased. In our included literature, van den Bosch et al\[[@B13]\] reported 2 patients who received HSCT due to a history of leukemia. Both of the patients had no history of chronic liver disease, and one of the patients was only 17 years old. However, both of the patients developed severe abdominal pain, hepatomegaly, and ascites approximately 2 wk after receiving HSCT, and the patients who received allogeneic transplantation progressed rapidly to upper gastrointestinal bleeding. Therefore, we believed that the occurrence of these 2 SOS cases is consistent with that mentioned by Al Jefri et al\[[@B4]\].

In recent years, preoperative chemotherapy has been widely used as a primary means of prolonging the survival rate of patients with liver metastasis from gastrointestinal cancer, especially colorectal cancer\[[@B14],[@B15]\]. Whereas, the use of several cytotoxic agents has been reported to link with irreversible liver damage\[[@B16]\]. Oxaliplatin, as an important composition of the modern chemotherapy regimens, has been proven several times in relation to the incidence of SOS\[[@B17]-[@B19]\]. Indeed, out of 13 patients in 11 case reports, 5 patients were related to chemotherapy for liver metastasis from colorectal cancer and gastric adenocarcinoma\[[@B17],[@B18],[@B20],[@B21]\]. All the patients received oxaliplatin-based adjuvant chemotherapy or S-1 and oxaliplatin (SOX) regimen chemotherapy. Five patients were identified with SOS during the chemotherapy cycle from 4 wk to 11 wk. All the 5 patients had abnormalities in laboratory indicators and moderate to severe splenomegaly. Overman et al\[[@B22]\] have shown that a 50% increase in spleen volume after oxaliplatin chemotherapy can be used as a predictor of SOS. These studies suggested that SOS should be considered if the cancer patient suddenly presented signs of splenomegaly or TBil elevation or persistent thrombocyte decline after a period of chemotherapy.

Furthermore, an animal study revealed that hepatic sinusoidal endothelial cells were equally sensitive to the toxic effects of PAs\[[@B23]\]. It has been reported that PAs-containing medicinal herbs (Tusanqi) can cause SOS\[[@B7],[@B24]\]. A systematic review\[[@B7]\] has demonstrated that Tusanqi is a principal cause of SOS in China and the disease could develop within several days. Moreover, the elevation levels of bilirubin and ALT were significantly associated with poor outcomes. As showed in our study, 465 (93.6%) of the 497 patients were caused by Tusanqi, and these patients were almost Chinese. Most of them used Tusanqi soaked in wine to relieve body pain or to treat traumatic injury, and some others took it as a nutritional supplement. The duration of intake of Tusanqi ranged from 3 d to 4 years. The differences in onset time may be linked to personal physique and dose and mode of the medicine herbs. In addition, we found that patients caused by Tusanqi more likely presented obvious clinical symptoms. This might be related to the mixed ingredients of the herbal medicines, which might contain a variety of toxic ingredients in addition to PAs. However, we were not sure if intaking PAs-containing herbs for multiple doses as a nutritional supplement was associated with the toxic accumulation and severer symptoms.

In view of the limitations of current diagnostic criteria for SOS, more non-invasive diagnosis methods have to be confirmed. Recently, an increasing number of studies have demonstrated that many characteristic imaging features can improve the early diagnostic efficiency for SOS\[[@B25]-[@B27]\]. Through analyzing MRI features of our included cases, we found that heterogeneous signals on T1WI/T2WI, heterogeneous enhancement of liver parenchyma, ascites, hepatomegaly, narrowing and blurring of intrahepatic IVC and hepatic veins, periportal edema, and gallbladder wall edema were the major MRI features of SOS. Most of the patients presented patchy or diffuse abnormal enhancement of liver parenchyma, some were focused on the second hepatic portal and presented "clover", "claw-shaped", or irregular enhancement, and a few presented hepatic lobe predominant enhancement. "Clover" and "claw-shaped" types of enhancement were the two distinctive MRI imaging features. This may be related to the opening of small blood vessels around the main hepatic veins resulting from obstruction of the hepatic sinus outflow tract, which resulted in an increase in blood supply. Ascites, periportal edema, and gallbladder wall edema may be associated with blockage of portal blood flow and impaired liver function.

In addition, several studies\[[@B7],[@B20],[@B21]\] reported that the patients who underwent hepatobiliary scans presented diffuse or reticular low signals in the liver parenchyma. Yoneda et al\[[@B21]\] conducted a correlation analysis between organic anion transporting polypeptides 1B3 (OATP1B3) and function of hepatocytes. The results showed that SOS led to hepatocyte function impairment and the signal in the hepatobiliary phase was related to the degree of hepatocyte injury. In addition, Choi et al\[[@B28]\] and Arakawa et al\[[@B29]\] reported SOS cases of focal hepatic lesions during oxaliplatin chemotherapy, which were misdiagnosed as liver metastases. This result suggested that sometimes the focal hepatic lesions should be considered as the occurrence of SOS, and liver biopsy instead of hepatectomy should be used as the initial examination plan. Furthermore, Guo et al\[[@B30]\] indicated that the lesion areas presenting hypo-intensity on SWI and T2\*WI were consistent with the abnormal enhancement in the portal vein phase in enhanced MRI. It may be related to the phenomenon that macrophages phagocytose and decompose red blood cells, and the decomposed red blood cells flow into the DISSE gap, which produces a large amount of hemosiderin. This result provided a new possibility for the diagnosis of SOS, especially for the patients with renal insufficiency or allergies to contrast agents.

This systematic review had several limitations. First, due to the low incidence of SOS, not enough high-quality literature was included in our study. Second, due to the lack of more complicate data, we were not able to analyze the relationship between MRI features and patient survival prognosis. In addition, some of the included literature was relatively obsolete, and the MRI models and parameters of each center were also different, which may lead to misjudgment of image results due to insufficient understanding of MRI signs.

Summary and outlook
-------------------

Although with low incidence, SOS still requires clinical attention because of its rapid progression and high mortality. In the West, in addition to being secondary to HSCT, the patients with liver metastasis from colorectal cancer should be highly alert to the occurrence of SOS. Furthermore, the hepatotoxic effects of some special drugs have to be brought to the attention of the public again. In the East, especially in China, while recognizing the efficacy of Chinese herbal medicine, we cannot ignore the potential harm to liver sinusoidal endothelial cells either. Ascites, abdominal pain and swelling, and jaundice are the common symptoms for the diagnosis of SOS. ALT, AST, ALP, GGT, and TBil can be used as predictors of liver function damage induced by SOS. Heterogeneous signals on T1WI/T2WI, heterogeneous enhancement of liver parenchyma, hepatomegaly, narrowing and blurring of intrahepatic IVC and hepatic veins, periportal edema, and gallbladder wall edema are the major MRI features of SOS. In addition, to further improve the non-invasive diagnosis of SOS, more MRI techniques need to be developed and applied, such as hepatobiliary scan of Gd-EOB MRI, SWI, and other functional imaging methods.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Sinusoidal obstruction syndrome (SOS), also referred to as veno-occlusive disease, is a rare liver vascular injury that is highly lethal. It is pathologically characterized by the damage of hepatic sinusoidal endothelial cells, impeded sinusoidal blood flow, congestive sinusoidal dilatation, and perisinusoidal fibrosis. Understanding the epidemiological characteristics and imaging features of SOS is vital for clinical diagnosis and treatment.

Research motivation
-------------------

Although biopsy is the golden standard for SOS diagnosis, it is invasive and cannot be easily implemented in practice work. Currently, the diagnosis of SOS usually depends on clinical criteria, such as the Baltimore criteria and the modified Seattle criteria. However, the diagnosis of SOS only based on clinical criteria is lack of high specificity. In recent years, magnetic resonance imaging (MRI) has been increasingly used in the differential diagnosis of SOS and shows a good prospect. Combing clinical information and MRI features of SOS could greatly improve the efficiency of SOS diagnosis.

Research objectives
-------------------

The main objective of this systematic review is to summarize the major etiologies, clinical symptoms, and MRI features of SOS.

Research methods
----------------

Published articles on PubMed, Web of Science, Wanfang Data, China Knowledge Resource Integrated, VIP, and Cochrane Library databases were searched. The search process mainly revolved around the etiologies, common clinical symptoms, and MRI imaging features of SOS. Last search was performed on January 28, 2019.

Research results
----------------

In total, 11 case reports and 18 case series were systematically reviewed. Chemotherapy for patients with liver metastasis of colorectal cancer, intake of medicine herbs containing pyrrolidine alkaloids (PAs, *e.g*. Tusanqi), and condition treatment prior to haemopoietic stem cell transplantation were the main etiologies of SOS. Hepatomegaly, ascites, abdominal swelling, and jaundice were the frequent clinical symptoms of SOS. Some laboratory indexes, including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, total bilirubin, and direct bilirubin had varying degrees of elevation. Hepatic parenchyma heterogeneity, ascites, hepatomegaly, narrowing of intrahepatic inferior vena cava and hepatic veins, edema around the portal vein, and gallbladder wall edema were the most common MRI imaging features of SOS.

Research conclusions
--------------------

Although this systematic review included not enough high-quality publications due to the low incidence of SOS, the findings of this review help clinicians to know about the epidemiological and imaging features of SOS and provide a more reliable and accurate diagnosis of SOS.

Research perspectives
---------------------

In the future, more high-quality prospective studies need to be conducted. Moreover, to further improve the diagnostic efficiency for SOS, some up-to-date imaging techniques, such as functional MRI, need to be developed and applied, including hepatobiliary scan of Gd-EOB MRI, susceptibility weighted imaging, and other functional imaging methods.
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